Biosimilars 2016

Renaissance Washington DC Dupont Circle Hotel

The Evolution of Patient Engagement at FDA

By John Whyte, MD

The drug approval process has traditionally relied heavily on scientific evidence for safety and efficacy. In a recent evolution...

Information in Action: A Conversation with Barbara Lopez Kunz

By William Looney, Editor-in-Chief, Pharmaceutical Executive Magazine

DIA Global Chief Executive Barbara Lopez Kunz was recently interviewed by William Looney, Editor-in-Chief of Pharmaceutical...

Disease Interception & the National Cancer Moonshot

By Ann Meeker-O’Connell, DIA Global Forum US Regional Editor, Carla Cartwright and Lindsay Cobbs

For the last few years in the US, patients, caregivers and advocates, the FDA, and drug developers have been focused on moving...

Introduction to Signal Detection and Data Mining

Pragmatic Approaches to Drug Safety Across the Premarketing and Postmarketing Continuum

The Westin Boston Waterfront